Pear expects $22M in revenue this year, as it banks on growing adoption of digital therapeutics

Dive Brief:

In its first earnings report since it went public, Pear Therapeutics met its guidance for 2021. The company, which makes digital therapeutics for substance use and insomnia, merged with a special-purpose acquisition company (SPAC)…

Source: www.healthcaredive.com – Read more